Elevate your local knowledge

Sign up for the iNFOnews newsletter today!

Select Region

Selecting your primary region ensures you get the stories that matter to you first.

Johnson & Johnson, Risperdal maker hit with $8B verdict

Johnson & Johnson, Risperdal maker hit with $8B verdict | iNFOnews.ca
FILE - In this July 30, 2013, file photo, people walk along a corridor at the headquarters of Johnson & Johnson in New Brunswick, N.J. A Philadelphia jury has ruled that Johnson & Johnson and Janssen Pharmaceuticals must pay $8 billion in punitive damages over an antipsychotic drug linked to the abnormal growth of female breast tissue in boys. A law firm for the plaintiff released a statement Tuesday, Oct. 8, 2019, saying the companies used an organized scheme to make billions of dollars while illegally marketing and promoting the drug called Risperdal. (AP Photo/Mel Evans, File)

PHILADELPHIA – A Philadelphia jury has decided that Johnson & Johnson and Janssen Pharmaceuticals should pay $8 billion over an antipsychotic drug that the plaintiff’s attorneys say is linked to the growth of female breast tissue in boys.

A law firm for the plaintiff released a statement Tuesday saying the companies used an organized scheme to make billions of dollars while illegally marketing and promoting the drug called Risperdal.

Johnson & Johnson says the jury’s award “is grossly disproportionate with the initial compensatory award in this case,” and that the company is “confident it will be overturned.”

News from © iNFOnews.ca, . All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.

Join the Conversation!

Want to share your thoughts, add context, or connect with others in your community?

Create a free account

iNFOTEL

Related Articles